Page last updated: 2024-11-05

chloroform

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6212
CHEMBL ID44618
CHEBI ID35255
MeSH IDM0004164

Synonyms (174)

Synonym
CHEBI:35255 ,
chcl3
1,1,1-trichloromethane
chloroformium pro narcosi
refrigerant r20
methane trichloride
chloroform, anhydrous, >=99%, contains 0.5-1.0% ethanol as stabilizer
r 20 (refrigerant)
nsc-77361
triclorometano
methane trichloride
freon 20
trichloroform
cloroformio
chloroforme
nci-c02686
trichlormethan
methyl trichloride
wln: gygg
trichloormethaan
r 20
formyl trichloride
methenyl trichloride
nsc77361
chloroform
trichloromethane
67-66-3
inchi=1/chcl3/c2-1(3)4/h1
methane, trichloro-
NCGC00090794-01
methenyl chloride
caswell no. 192
hsdb 56
rcra waste number u044
ai3-24207
triclorometano [italian]
rcra waste no. u044
trichloormethaan [dutch]
einecs 200-663-8
un1888
nsc 77361
chloroform [un1888] [poison]
ccris 137
cloroformio [italian]
trichlormethan [czech]
chloroforme [french]
brn 1731042
epa pesticide chemical code 020701
chloroform [nf xvii]
chloroform, for hplc, >=99.8%, contains 0.5-1.0% ethanol as stabilizer
chloroform, acs reagent, >=99.8%, contains amylenes as stabilizer
chloroform, >=99%, pcr reagent, contains amylenes as stabilizer
chloroform, puriss. p.a., acs reagent, >=99.8% (chloroform + ethanol, gc)
chloroform, anhydrous, contains amylenes as stabilizer, >=99%
L023971
C0819
chloroform bp
hcc 20
CHEMBL44618
chloroformum
AKOS000269026
chloroformwith ethanol
chloroformwith amylene
chloroform, acs
A835850
tris(chloranyl)methane
NCGC00090794-02
tox21_202494
NCGC00260043-01
tox21_111024
cas-67-66-3
dtxsid1020306 ,
dtxcid10306
methylidyne trichloride
chloroform, 99.8%, acs reagent stabilized with ethanol
7v31yc746x ,
ec 200-663-8
unii-7v31yc746x
4-01-00-00042 (beilstein handbook reference)
chloroform [nf]
FT-0623661
chloroformum [hpus]
chloroform [green book]
chlorobutanol impurity a [ep impurity]
chloroform [vandf]
chloroform [mart.]
chloroform [iarc]
chloroform [usp-rs]
chloroform [mi]
chloroform [hsdb]
chloroform [inci]
chloroform [ii]
chloroform [who-dd]
gtpl2503
BRD-K88785477-001-01-8
chloroform chcl3
chloroforrn
hccl3
chloroform-
trichlormethane
chloro form
trichloro- methane
ccl3h
chloro-form
cloroform
chlorform
trichloro-methane
chloroform, ethanol-free
chloroform stabilized with 50-200 ppm amylene acs reagent grade
un 1888
f 20
chloroform, hplc grade
chloroform, environmental grade
trichlormethan/chloroform
chloroform, spectrophotometric grade
F0001-1775
chloroform, contains 100-200 ppm amylenes as stabilizer, >=99.5%
mfcd00000826
chloroform (stabilized with ethanol)
chloroform (stabilized with 2-methyl-2-butene)
chloroform, jis special grade, >=99.0%
chloroform, for hplc
chloroform, acs reagent, >=99.8%, contains 0.5-1.0% ethanol as stabilizer
chloroform, for hplc, >=99.8%
residual solvent class 2 - chloroform, united states pharmacopeia (usp) reference standard
chloroform, contains ethanol as stabilizer, meets analytical specification of dab9, bp, 99-99.4% (gc)
chloroform, contains ethanol as stabilizer, acs reagent, >=99.8%
chloroform, acs spectrophotometric grade, >=99.8%, contains amylenes as stabilizer
chloroform, analytical standard
chloroform, purification grade, >=99%
chloroform, biotech. grade, >=99.8%, contains 0.5-1.0% ethanol as stabilizer
chloroform, saj first grade, >=99.0%, contains 0.4-0.8% ethanol
chloroform, for hplc, >=99.8% (chloroform + ethanol, gc)
chloroform, technical, amylene stabilized, >=99% (gc)
chloroform, contains amylenes as stabilizer, acs reagent, >=99.8%
chloroform, acs spectrophotometric grade, >=99.8%, contains 0.5-1.0% ethanol as stabilizer
chloroform, reagentplus(r), >=99.8%, contains 0.5-1.0% ethanol as stabilizer
chloroform, puriss. p.a., reag. iso, reag. ph. eur., 99.0-99.4% (gc)
chloroform, saj super special grade, >=99.0%
chloroform, for hplc, >=99.8%, amylene stabilized
chloroform, for hplc, >=99.5%
chloroform, lr, contains 100 ppm amylene as stabilizer, >=99%
chloroform, acs reagent, reag. ph. eur., contains ethanol as stabilizer
chloroform, pharmaceutical secondary standard; certified reference material
chloroform, p.a., 99.8%
chloroform, ar, contains 100 ppm amylene as stabilizer, >=99.5%
chloroform, uv hplc spectroscopic, 99.0%, contains 0.6-1.0% ethanol
chloroform, p.a., acs reagent, reag. iso, 99.8%, contains 50 ppm amylene
chloroform, uv hplc spectroscopic, 99.9%, contains 50 ppm amylene
chloroform, technical grade, 95%, contains 50 ppm amylene
residual solvent - chloroform, pharmaceutical secondary standard; certified reference material
chloroform, p.a., acs reagent, 99.8%, contains 0.005% amylene
chloroform, ar, contains 1-2% ethanol as stabilizer, >=99.5%
trichloromethane 5000 microg/ml in methanol
trichloromethane 10 microg/ml in methanol
trichloromethane 100 microg/ml in methanol
r 20 (van)
trichloromethane, 9ci
8013-54-5
chloroform with amylene hplc grade
chloroform, hplc grade stabilized with ethanol
DB11387
chloroform 5000 microg/ml in methanol
chloroform 100 microg/ml in methanol
Q172275
nci-co2686
r 20(refrigerant)
chloroform (iarc)
chloroform (ii)
chloroform (usp-rs)
chlorobutanol impurity a (ep impurity)
chloroform (mart.)
pesticide code: 020701
r-20

Research Excerpts

Overview

Chloroform (CF) is a widely used industrial chemical that can also pollute the environment. It is a recognised cause of acute liver injury, although now rarely encountered in clinical practice. Chloro Form is a common contaminant in the drinking water.

ExcerptReferenceRelevance
"Chloroform (CF) is a widely used chemical reagent and disinfectant and a probable human carcinogen. "( Degradation of Chloroform by Zerovalent Iron: Effects of Mechanochemical Sulfidation and Nitridation on the Kinetics and Mechanism.
Bylaska, EJ; Chen, J; Gong, L; He, F; He, K; Hu, Y; Tratnyek, PG, 2023
)
2.71
"Chloroform is a widely used industrial chemical that can also pollute the environment. "( Cytotoxicity and genotoxicity evaluation of chloroform using
Gao, T; Li, A; Li, X; Zhang, M, 2023
)
2.61
"Chloroform is a recognised cause of acute liver injury, although now rarely encountered in clinical practice. "( Delayed onset of liver injury after intentional chloroform overdose: a case report and literature review.
Brightmore, A; Panetta, M; Waring, WS, 2019
)
2.21
"Chloroform is an example of a halogenated organic compound with natural formation as its primary source."( Arctic and Subarctic Natural Soils Emit Chloroform and Brominated Analogues by Alkaline Hydrolysis of Trihaloacetyl Compounds.
Albers, CN; Flores, EMM; Jacobsen, OS; Johnsen, AR, 2017
)
1.44
"Chloroform is a common contaminant in the drinking water. "( 3-methyadenine attenuates chloroform-induced hepatotoxicity via autophagy activation.
Chen, C; Li, X; Wang, L, 2018
)
2.22
"Chloroform acts as an effective hydrogen atom donor for primary, secondary, and tertiary alkyl radicals, although significant chlorination was also observed with unstrained tertiary carboxylic acids."( Chloroform as a hydrogen atom donor in Barton reductive decarboxylation reactions.
Coote, ML; Ho, J; Ko, EJ; Meana-Pañeda, R; Savage, GP; Truhlar, DG; Tsanaktsidis, J; Williams, CM; Zheng, J, 2013
)
2.55
"Chloroform (CF) is a widespread groundwater contaminant not susceptible to aerobic degradation. "( Bioaugmentation with distinct Dehalobacter strains achieves chloroform detoxification in microcosms.
Edwards, EA; Griffiths, DR; Higgins, S; Justicia-Leon, SD; Löffler, FE; Mack, EE; Tang, S, 2014
)
2.09
"Chloroform is an organic solvent used as an intermediate in the synthesis of various fluorocarbons. "( Influence of sexual dimorphism on pulmonary inflammatory response in adult mice exposed to chloroform.
Bezerra, FS; Campos, KK; de Oliveira, TH; Lima, WG; Pena, KB; Soares, NP,
)
1.79
"The chloroform is a substance that presents a significant risk to or via the aquatic environment. "( Wastewater reuse: modeling chloroform formation.
Ferra, I; Marques, A; Rebelo, A; Silva, MM, 2016
)
1.29
"Chloroform is a potent central nervous system and respiratory depressant. "( Lethal complications after poisoning with chloroform--case report and literature review.
Lionte, C, 2010
)
2.07
"Chloroform is a potent inhibitor of metabolism and no known organism uses it as a growth substrate."( Chloroform respiration to dichloromethane by a Dehalobacter population.
Duhamel, M; Dworatzek, S; Edwards, EA; Grostern, A, 2010
)
2.52
"Chloroform (CF, CHCl(3)) is a recalcitrant and toxic environmental pollutant. "( Complete chloroform dechlorination by organochlorine respiration and fermentation.
Koenig, J; Lee, M; Low, A; Manefield, M; Michaelsen, A; Zemb, O, 2012
)
2.24
"Chloroform (CHCl(3)) is an environmental contaminant widely distributed around world, as well as a natural compound formed in various aquatic and terrestrial environments. "( Assessing the role of trichloroacetyl-containing compounds in the natural formation of chloroform using stable carbon isotopes analysis.
Albers, CN; Breider, F; Hunkeler, D, 2013
)
2.06
"Chloroform (CHCl(3)) is a chemical for which there are PBPK models available in different species and multiple sites of toxicity."( Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
Genter, MB; Kedderis, GL; Li, Z; Lipscomb, JC; Rieth, S; Sasso, AF; Schlosser, PM; Snawder, JE, 2013
)
1.34
"Chloroform is a nongenotoxic-cytotoxic carcinogen in rodents. "( Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation.
Butterworth, BE; Conolly, RB; Gargas, ML; Tan, YM, 2003
)
2.02
"Chloroform (CHCl3) is a near-ubiquitous environmental contaminant, a by-product of the disinfection of drinking water sources and a commercially important compound. "( The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform.
Alcasey, S; Barton, HA; Evans, MV; Laskey, J; Lipscomb, JC; Snawder, JE; Tornero-Velez, R, 2004
)
1.98
"Chloroform (CF) is an important priority pollutant contaminating groundwater. "( Riboflavin- and cobalamin-mediated biodegradation of chloroform in a methanogenic consortium.
Field, JA; Guerrero-Barajas, C, 2005
)
2.02
"Chloroform is a non-genotoxic compound that is present in drinking water and ambient air as a result of water chlorination but whose carcinogenic mechanism in humans is unknown. "( Reduced mitochondrial membrane potential and metabolism correspond to acute chloroform toxicity of in vitro hepatocytes.
Balcarcel, RR; Fries, S; Hartig, S,
)
1.8
"Chloroform is a carcinogen in rodents and its carcinogenicity is secondary to events associated with cytotoxicity and regenerative cell proliferation. "( Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
Andersen, ME; Borghoff, SJ; Clewell, HJ; Conolly, RB; Gargas, ML; Liao, KH; Tan, YM, 2007
)
1.99
"Chloroform is a drinking water contaminant that has been demonstrated to be carcinogenic to mice and rats resulting in an increased incidence of liver and kidney tumors, respectively. "( Chloroform induction of ornithine decarboxylase activity in rats.
Guion, C; Pereira, MA; Savage, RE; Westrich, C, 1982
)
3.15
"Chloroform is an important environmental water and air pollutant. "( Nasal toxicity of chloroform in male F-344 rats and female B6C3F1 mice following a 1-week inhalation exposure.
Butterworth, BE; Harden, R; Larson, JL; Méry, S; Morgan, KT; Wolf, DC, 1994
)
2.07
"Chloroform is a known contaminant of chlorinated drinking water and of swimming pool water disinfected with chlorine or one of its derivatives. "( Evaluation of dermal and respiratory chloroform exposure in humans.
Allaire, S; Ayotte, P; Dewailly, E; Lavoie, R; LeBlanc, A; Levallois, P; Lévesque, B; Prud'Homme, D, 1994
)
2
"Chloroform is a liver carcinogen in mice and a kidney carcinogen in rats. "( Levels of myc, fos, Ha-ras, met and hepatocyte growth factor mRNA during regenerative cell proliferation in female mouse liver and male rat kidney after a cytotoxic dose of chloroform.
Butterworth, BE; Goldsworthy, SM; Larson, JL; Sprankle, CS, 1996
)
1.93
"Chloroform is a nongenotoxic-cytotoxic liver and kidney carcinogen and nasal toxicant in some strains and sexes of rodents. "( Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice.
Butterworth, BE; Constan, AA; Everitt, JI; Gonzalez, FL; Kedderis, GL; Peters, JM; Sprankle, CS; Wong, BA, 1999
)
2.11
"Chloroform is a nongenotoxic-cytotoxic carcinogen in rodent liver and kidney, including the female B6C3F1 mouse liver. "( Chloroform inhalation exposure conditions necessary to initiate liver toxicity in female B6C3F1 mice.
Butterworth, BE; Constan, AA; Everitt, JI; Wong, BA, 2002
)
3.2
"Chloroform (CHCl3) is an established rodent carcinogen and a prevalent contaminant of chlorine-disinfected drinking water. "( Site-specific modulation of carcinogen-induced gastrointestinal tract nuclear anomalies in B6C3F1 mice by chloroform.
Daniel, FB; Olson, GR; Reddy, TV; Stober, JA,
)
1.79

Effects

Chloroform has been used over decades in anesthesia before it was replaced by other volatile anesthetics like halothane or sevoflurane. Its chloroform extract has the greatest killer activity against E. coli. It has a high solubility for lipids and accumulation of lipids in the liver might become a risk factor for liver injury.

ExcerptReferenceRelevance
"Chloroform has a high solubility for lipids and accumulation of lipids in the liver might become a risk factor for liver injury by chloroform."( Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report.
Aikata, H; Arihiro, K; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Oka, S; Suehiro, Y; Tsuge, M; Uchida, T, 2023
)
1.86
"Chloroform has a high solubility for lipids and accumulation of lipids in the liver might become a risk factor for liver injury by chloroform."( Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report.
Aikata, H; Arihiro, K; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Oka, S; Suehiro, Y; Tsuge, M; Uchida, T, 2023
)
1.86
"Chloroform has been used over decades in anesthesia before it was replaced by other volatile anesthetics like halothane or sevoflurane. "( Chloroform is a potent activator of cardiac and neuronal Kir3 channels.
Döring, F; Gergs, U; Kollert, S; Wischmeyer, E, 2020
)
3.44
"Its chloroform extract has the greatest killer activity against E."( [The association of pigment-containing lipid and low-molecular bacteriocin of Erwinia carotovora].
Maksimenko, LA; Tovkach, FI,
)
0.61
"Chloroform has been for a long time considered only as an anthropogenic contaminant. "( Demonstrating a natural origin of chloroform in groundwater using stable carbon isotopes.
Breider, F; Hunkeler, D; Jacobsen, OS; Laier, T, 2012
)
2.1
"Chloroform chemi-sensor has been fabricated by proficient exploitation of CuO microsphere as redox mediator."( Sensitive chemi-sensor for environmental applications as marker of chloroform in aqueous solution.
Akhtar, K; Alamry, KA; Asiri, AM; Faisal, M; Khan, SB; Rahman, MM, 2013
)
1.35
"Chloroform has been assessed as a Priority Substance under the Canadian Environmental Protection Act. "( Chloroform: exposure estimation, hazard characterization, and exposure-response analysis.
Beauchamp, R; Long, G; Meek, ME; Moir, D; Turner, L; Walker, M,
)
3.02
"Chloroform has been reported to induce inhalation intoxication in the respiratory tract. "( Role of ryanodine receptors in chloroform-induced contraction in Swine tracheal smooth muscle.
Chan, MH; Chen, HH; Lin, YR, 2002
)
2.04
"Chloroform has been regarded as a renal carcinogen, based on results obtained with Osborne Mendel (OM) rats. "( Bioactivation, toxicokinetics and acute effects of chloroform in Fisher 344 and Osborne Mendel male rats.
Chieco, P; Gemma, S; Testai, E; Vittozzi, L,
)
1.83
"Chloroform has been reported to induce cancer in rodents after chronic administration of high doses by gavage. "( Mechanistic considerations for carcinogenic risk estimation: chloroform.
Fox, TR; Quast, JF; Reitz, RH, 1982
)
1.95
"Chloroform has been the most widely used solvent in endodontics, but due to concerns about its safety, alternatives have been sought. "( Endodontic retreatment with halothane versus chloroform solvent.
Wilcox, LR, 1995
)
1.99
"Chloroform has been found in potable water and there is concern that significant dermal absorption may arise from daily bathing and other activities. "( In vitro and in vivo percutaneous absorption of 14C-chloroform in humans.
Chu, I; Dick, D; Ng, KM; Sauder, DN, 1995
)
1.98
"Chloroform has been shown to induce hepatocellular carcinomas in female B6C3F1 mice when administered by gavage, but not when given in drinking water. "( Lack of chloroform-induced DNA repair in vitro and in vivo in hepatocytes of female B6C3F1 mice.
Butterworth, BE; Larson, JL; Sprankle, CS, 1994
)
2.17
"Chloroform has obvious hepato-, nephro-toxicity and carcinogenicity. "( Studies on the toxicity and maximum allowable concentration of chloroform.
Chen, ZQ; Jiang, XZ; Li, LH; Liang, YX; Wang, YL; Zhou, YF, 1993
)
1.97
"Chloroform has the great advantage of being fireproof, but proper fume hoods should be used."( Comparison of ether and chloroform for Soxhlet extraction of freeze-dried animal tissues.
Firth, NL; Ross, DA; Thonney, ML,
)
1.16

Actions

Chloroform does not cause a chemical labyrinthectomy as previously assumed, although it is severely ototoxic. It can also activate enzymes.

ExcerptReferenceRelevance
"Chloroform can also activate enzymes."( Noteworthy Chemistry of Chloroform.
Alston, TA, 2016
)
1.46
"Chloroform was seen to inhibit both myofibrillar enzymes."( Subcellular effects of some anesthetic agents on rat myocardium.
Alto, LE; Dhalla, NS; Lee, SL, 1979
)
0.98
"Chloroform does not cause a chemical labyrinthectomy as previously assumed, although it is severely ototoxic."( Histopathology of chloroform-induced inner ear damage.
Hu, K; Schwarz, DW; Schwarz, IE, 1988
)
1.33

Treatment

Chloroform treatment and shifts in temperature of producer cells released approximately similar amounts of phage as did mitomycin induction. The chloroform-treated rats also developed renal tubular necrosis with large increases in plasma creatinine and urea nitrogen.

ExcerptReferenceRelevance
"Chloroform used for retreatment had an adverse effect on the bond strength of Resilon/Epiphany SE after root canal reobturation."( Push-out bond strength of Resilon/Epiphany self-etch to intraradicular dentin after retreatment: a preliminary study.
Hasheminasab, M; Sabeti, MA; Shafiei, F; Shamshiri, AR; Shokouhinejad, N, 2010
)
1.08
"The chloroform treatment of the bacteriocin preparation did not affect its killer activity against both E."( [The association of pigment-containing lipid and low-molecular bacteriocin of Erwinia carotovora].
Maksimenko, LA; Tovkach, FI,
)
0.61
"The chloroform-methanol treatment of the SC shifted the dip position, which represents a convex downward shape of the spectra, to a higher frequency. "( Terahertz wave techniques using a metal mesh for evaluating the components of the stratum corneum.
Guan, Y; Kawase, K; Mizukoshi, K; Ogura, H; Yonekura, K, 2013
)
0.95
"Chloroform treatment did not significantly affect GST activities in erythrocytes of control subjects while the activities of erythrocyte total GST and alpha-GST were significantly increased in all anemic patients (P<0.001). "( Differential expression of glutathione-S-transferase isoenzymes in various types of anemia in Taiwan.
Chiang, WL; Chu, SC; Hsieh, YS; Lu, TA; Yang, SF, 2007
)
1.78
"The chloroform-treated granules were able to be reused over four fed-batch cultures, with pH adjustment."( Biological hydrogen production using chloroform-treated methanogenic granules.
Chen, S; Hu, B, 2008
)
1.1
"Chloroform treatment and shifts in temperature of producer cells released approximately similar amounts of phage as did mitomycin induction, suggesting an effect on release rather than on synthesis of the virus."( Properties of the virulent form of a mitomycin C- or temperature-induced thermophilic bacteriophage.
Barridge, BD; Holmes, D; Wojtkiewicz, P, 1981
)
0.98
"Chloroform treatment did not affect the activity of N-nitrosodimethylamine N-demethylase in pretreated rats; the high dose increased the activity in control rats."( Different contributions of cytochrome P450 2E1 and P450 2B1/2 to chloroform hepatotoxicity in rat.
Aoyama, T; Elovaara, E; Gelboin, HV; Klockars, M; Nakajima, T; Okino, T; Riihimäki, V; Vainio, H, 1995
)
1.25
"Chloroform treatment produced similar band patterns and at least as good an enzyme yield as ultrasonic disintegration and was equally simple and fast to perform."( Evaluation of five different methods to prepare bacterial extracts for the identification of beta-lactamases by isoelectric focusing.
Arstila, T; Huovinen, P; Jacoby, GA, 1993
)
1.01
"The chloroform-treated rats also developed renal tubular necrosis with large increases in plasma creatinine and urea nitrogen, which were completely ameliorated by DMSO."( Late dimethyl sulfoxide administration provides a protective action against chemically induced injury in both the liver and the kidney.
Gandolfi, AJ; Lind, RC, 1997
)
0.78
"Chloroform-treated rats of both sexes survived better than the controls, though both groups had a high incidence of non-neoplastic respiratory and renal disease."( Safety evaluation of toothpaste containing chloroform. II. Long term studies in rats.
Palmer, AK; Roe, FJ; Street, AE; Van Abbé, NJ; Worden, AN,
)
1.12
"Chloroform treatment failed to remove inhibitors in normal and jaundiced plasma and did not prevent inhibition of colorimetry by bilirubin."( A comparison of methods of removing inhibitors to the chromogenic Limulus assay in normal and jaundiced blood.
Giles, GR; Ingoldby, CJ; Skinner, C, 1986
)
0.99
"Chloroform-treated sera exhibited significantly declined levels of C1-INH, C3 and C4 as well as of circulating immune complexes."( In vitro effects of organic solvents on immunity indicators in serum.
Absolonová, O; Murgasová, I; Starsia, Z; Stefanovic, J, 1987
)
0.99
"Treatment with chloroform, which is a non-genotoxic carcinogen, did not induce DNA damage in the liver or stomach."( Assessment of the in vivo genotoxicity of cadmium chloride, chloroform, and D,L-menthol as coded test chemicals using the alkaline comet assay.
Fukuyama, T; Matsumoto, K; Nakashima, N; Wada, K, 2015
)
1

Toxicity

Turbine was most toxic followed by halothane and chloroform, which caused similar levels of cell injury. Fumonisins B1 and B2 were extracted from the CM by water, but not chloroforms. The results obtained are sufficiently reproducible to yield an order of cytotoxicity.

ExcerptReferenceRelevance
"The oral LD50'S of clioquinol, histamine and chloroform and the intravenous LD50 of histamine were determined separately in male and female mice of the Tif : MAGf (SPF), Tif : MF2f (SPF), C3H/Tif Bomf, DBA2/J Bomf, C57Bl/6J/Bomf and A/J Bomf strains."( Comparison of the acute toxicity of clioquinol, histamine, and chloroform in different strains of mice.
Pericin, C; Thomann, P, 1979
)
0.76
" CD, known to potentiate hepatotoxic and lethal effects of halomethanes in rats, failed to potentiate the toxic effects of any of these three halomethanes in gerbils."( Hepatotoxicity and lethality of halomethanes in Mongolian gerbils pretreated with chlordecone, phenobarbital or mirex.
Cai, Z; Mehendale, HM, 1991
)
0.28
" Significantly diminished formate oxidation by cells exposed to either CR or TCE without acetylene compared with that with acetylene suggests that the solvents themselves were not toxic under the experimental conditions but their transformation products were."( Product toxicity and cometabolic competitive inhibition modeling of chloroform and trichloroethylene transformation by methanotrophic resting cells.
Alvarez-Cohen, L; McCarty, PL, 1991
)
0.52
" t-Butanol, pentanol, hexanol, and octanol significantly decreased the LD50 of CCl4."( Potentiation of CCl4 and CHCl3 hepatotoxicity and lethality by various alcohols.
Mehendale, HM; Ray, SD, 1990
)
0.28
" Fumonisins B1 and B2 were extracted from the CM by water, but not chloroform/methanol, and were present in the toxic diets at concentrations of 93-139 and 82-147 ppm, respectively."( Comparative studies of hepatotoxicity and fumonisin B1 and B2 content of water and chloroform/methanol extracts of Fusarium moniliforme strain MRC 826 culture material.
Bacon, CW; Norred, WP; Plattner, RD; Voss, KA, 1990
)
0.74
" The minimum concentration of the chemicals at which enzyme leakage from hepatocytes was significantly increased was defined as the lowest toxic concentration (TCL0)."( [Toxicity assessments of chemical substances using primary culture of rat hepatocytes].
Fang, JF; Ishikawa, S; Kitagawa, Y; Manabe, S; Nakajima, K; Wada, O; Yanagisawa, H, 1986
)
0.27
" There was even a toxic response form the mixture at concentrations where the chemicals alone yielded no such response."( Assessment of the toxicity of chemical mixtures with isolated rat hepatocytes: cadmium and chloroform.
Stacey, NH, 1987
)
0.49
"Carbon tetrachloride (CCl4) added to isolated rat hepatocytes produces toxic effects which were assessed by monitoring the release of aspartate aminotransferase (ASAT)."( Inhibiting or potentiating effects of flavonoids on carbon tetrachloride-induced toxicity in isolated rat hepatocytes.
Perrissoud, D; Testa, B, 1986
)
0.27
" CCl4 was approximately 16 times more toxic than CHCl3 to the hepatocytes."( Mechanisms of chloroform and carbon tetrachloride toxicity in primary cultured mouse hepatocytes.
Askari, AB; Goldblatt, PJ; Klaunig, JE; Lacher, DA; Pereira, MA; Ruch, RJ; Schultz, NE, 1986
)
0.63
" In renal cortical slices, deuterated-CHCl3 was less toxic than CHCl3."( Role of intrarenal biotransformation in chloroform-induced nephrotoxicity in rats.
Hewitt, WR; Hook, JB; Smith, JH, 1985
)
0.54
" In this investigation, we have found that sensitivity to CHCl3 correlates with the capacity of the kidney to metabolize CHCl3 to the toxic metabolite phosgene (COCl2)."( Strain and sex differences in chloroform-induced nephrotoxicity. Different rates of metabolism of chloroform to phosgene by the mouse kidney.
George, JW; Pohl, LR; Satoh, H,
)
0.42
" Effect of CD on 48 hr LD50 of BrCCl3 was also examined using the method of moving averages."( Potentiation of bromotrichloromethane hepatotoxicity and lethality by chlordecone preexposure in the rat.
Agarwal, AK; Mehendale, HM,
)
0.13
" Dosages of 5 mg/kg of chlordecone did not potentiate CHCl3 toxicity, but higher dosages (10-50 mg/kg) enhanced the toxic response in a dose-dependent manner."( A semiquantitative morphologic assessment of chlordecone-potentiated chloroform hepatotoxicity.
Côté, MG; Iijima, M; Plaa, GL, 1983
)
0.5
" Pretreatment with phenobarbital enhanced the toxic response of renal cortical slices to CHCl3 in vitro as indicated by decreased p-aminohippurate and tetraethylammonium accumulation."( Mechanism of chloroform nephrotoxicity. IV. Phenobarbital potentiation of in vitro chloroform metabolism and toxicity in rabbit kidneys.
Bailie, MB; Hook, JB; Newton, JF; Smith, JH, 1984
)
0.64
" These data support the concept that phosgene is the toxic intermediate in chloroform metabolism."( Effect of cysteine, diethyl maleate, and phenobarbital treatments on the hepatotoxicity of [1H]chloroform.
Anders, MW; Stevens, JL, 1981
)
0.71
" The results obtained are sufficiently reproducible to yield an order of cytotoxicity: hexachlorobutadiene is about 100-fold more toxic than chloroform or 1,2-dichloroethane; whereas, 1,1,1-trichloroethane is 10-fold more toxic than these two compounds."( [A study of the cytotoxicity of chloroform, 1-2-dichloroethane, 1,1,1-trichloroethane and hexachlorobutadiene to mouse L cells (author's transl)].
Chau, N; Elias, Z; Hartemann, P, 1981
)
0.75
" Nasal passages were also examined for toxic responses."( The toxicity of 1-week exposures to inhaled chloroform in female B6C3F1 mice and male F-344 rats.
Butterworth, BE; Larson, JL; Méry, S; Morgan, KT; Wolf, DC, 1994
)
0.55
" Results of qualitative and quantitative covalent binding of tienilic acid metabolite(s) to human liver microsomes were then compared to those obtained with two drugs leading to direct toxic hepatitis, namely, acetaminophen and chloroform."( Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.
Ballet, F; Beaune, PH; Bonierbale, E; Catinot, R; Challine, D; Dansette, PM; Gautier, JC; Lecoeur, S; Mansuy, D; Valadon, P,
)
0.32
" Turpentine was most toxic followed by halothane and chloroform, which caused similar levels of cell injury."( Cytotoxic effects of gutta-percha solvents.
Barbosa, SV; Burkard, DH; Spångberg, LS, 1994
)
0.54
" Furthermore, the toxic effect of CHCl3 on cardiac myocytes was time dependent."( Evaluation of chloroform cardiotoxicity utilizing a modified isolated rat cardiac myocytes.
Abdel-Rahman, MS; el-Shenawy, NS, 1993
)
0.65
" This study was designed to investigate the toxic effect of CHCl3 on isolated male rat hepatocytes using several toxicity parameters."( The mechanism of chloroform toxicity in isolated rat hepatocytes.
Abdel-Rahman, MS; el-Shenawy, NS, 1993
)
0.63
" None of those receiving the 30- or 60-micrograms CMR dose and none of the placebo recipients experienced any adverse effects."( Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever.
Fries, LF; Waag, DM; Williams, JC, 1993
)
0.54
"A simple and safe device for spreading ultrathin sections for electron microscopy is described."( A simple and safe device for spreading ultrathin sections with chloroform.
Edén, UM; Olson, LW, 1993
)
0.53
" These results suggest that NDPS and its metabolites are not directly toxic to the kidney and are not converted into the ultimate nephrotoxic species by the kidney."( Potential metabolism and cytotoxicity of N-(3,5-dichlorophenyl)succinimide and its hepatic metabolites in isolated rat renal cortical tubule cells.
Harvison, PJ; Henesey, CM, 1995
)
0.29
" The model predicted the observed toxic response after the capacity for chloroform metabolism was increased by a factor of 3 from the value estimated using human liver microsomes."( Biologically based dose response model for hepatic toxicity: a mechanistically based replacement for traditional estimates of noncancer risk.
Butterworth, BE; Conolly, RB, 1995
)
0.52
" This study confirmed that 300 ppm is extremely toxic and would be inappropriate for longer-term cancer studies."( A 90-day chloroform inhalation study in F-344 rats: profile of toxicity and relevance to cancer studies.
Butterworth, BE; Jamison, KC; Larson, JL; Leininger, JR; Méry, S; Morgan, KT; Templin, MV; Wolf, DC; Wong, BA, 1996
)
0.71
" The purpose of defatting and freeze-drying was to facilitate subsequent sterilisation by eliminating the barrier to diffusion of the gas into bone, to lower residual levels of ethylene oxide and its toxic by-products, to eliminate alloantigens and to make storage possible at room temperature."( Preparation of bank bone using defatting, freeze-drying and sterilisation with ethylene oxide gas. Part 1. Experimental evaluation of its efficacy and safety.
Kakiuchi, M; Nishimura, A; Ono, K; Shiokawa, H, 1996
)
0.29
" The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical."( Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.
Fariss, MW; Lippman, HR; Mumaw, VR; Ray, SD, 1997
)
0.5
" In addition to causing more persistent liver toxicity than CHCl3, BDCM also appears to be slightly more toxic to the kidney at lower doses."( Trihalomethane comparative toxicity: acute renal and hepatic toxicity of chloroform and bromodichloromethane following aqueous gavage.
Lilly, PD; Pegram, RA; Ross, TM, 1997
)
0.53
" As the toxicity of these trihalomethanes (THMs) has most often been studied with corn oil as the vehicle of administration, the objectives of this study were to assess hepatotoxicity after exposure to single, low dosages of CHCl3 and BDCM given orally in an aqueous vehicle to estimate a lowest-observed-adverse-effect level (LOAEL) and a no-observed-adverse-effect level (NOAEL) and to compare toxic potency."( NOAEL and LOAEL determinations of acute hepatotoxicity for chloroform and bromodichloromethane delivered in an aqueous vehicle to F344 rats.
Keegan, TE; Pegram, RA; Simmons, JE, 1998
)
0.54
" Animals were evaluated for toxic effects, including assessment of toxicant-induced alterations to the ocular and respiratory systems."( Acute inhalation toxicity of neutralized chemical agent identification sets (CAIS) containing agent in chloroform.
Johnson, R; McVeety, B; Morgan, EW; Olajos, EJ; Phelps, RL; Renne, RA; Salem, H,
)
0.35
" Administration of ABT completely protected against the hepatic, renal, and nasal toxic effects of chloroform."( Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice.
Butterworth, BE; Constan, AA; Everitt, JI; Gonzalez, FL; Kedderis, GL; Peters, JM; Sprankle, CS; Wong, BA, 1999
)
0.88
" The association of this adduct with the toxic effects of chloroform makes it a very good candidate as the primary critical alteration in the sequence of events leading to cell death caused by chloroform."( Correlation of a specific mitochondrial phospholipid-phosgene adduct with chloroform acute toxicity.
De Angelis, G; Di Consiglio, E; Testai, E; Vittozzi, L, 2001
)
0.79
" Thus, the rate of production of toxic metabolites and the subsequent rate of cellular damage produced by a continual exposure of approximately 10 ppm chloroform are less than the maximum rates at which hepatocytes can detoxify those metabolites and repair any induced cellular damage."( Chloroform inhalation exposure conditions necessary to initiate liver toxicity in female B6C3F1 mice.
Butterworth, BE; Constan, AA; Everitt, JI; Wong, BA, 2002
)
1.96
"High concentrations of organic solvents have adverse effects on the health of professional workers."( [Solvents for the removal of gutta-percha from root canals. 2. Side effects of chloroform, halothane and xylene].
Moorer, WR; Schuur, AH; Wesselink, PR, 2004
)
0.55
"Both solvents proved toxic at the same levels of concentrations of 1:100 and 1:400 (P>."( Cytotoxicity evaluation of gutta-percha solvents: Chloroform and GP-Solvent (limonene).
Kamolroongwarakul, R; Pewklieng, L; Suwannawong, SK; Vajrabhaya, LO, 2004
)
0.58
" Thus, the generation of transgenic promoter-luciferase animals for genes regulated by specific toxic processes, coupled with real-time evaluation of site-specific gene expression may provide novel, non-invasive biomarkers which are predictive of developing toxicity in vivo."( Biophotonic imaging in HO-1.luc transgenic mice: real-time demonstration of gender-specific chloroform induced renal toxicity.
Driver, R; Lynch, AM; McClure, F; Meakin, J; Schenck, E; Walker, S; Weir, LR, 2005
)
0.55
" Antifungal and toxic activities of crude extract, fractions and a pure isolated compound exhibited statistically significant activities."( Antimicrobial and cytotoxicity activities of the medicinal plant Primula macrophylla.
Ahmad, M; Alam, F; Najmus-Saqib, Q, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Demographics, disease severity, markers of disease activity before and after the combination therapy, and incidence of adverse events were evaluated."( The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.
Li, Y; Shi, Q; Tang, FL; Zhang, FC; Zhang, W; Zhang, X; Zhao, LD, 2010
)
0.64
" Most of the adverse events noted during this study were mild."( The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.
Li, Y; Shi, Q; Tang, FL; Zhang, FC; Zhang, W; Zhang, X; Zhao, LD, 2010
)
0.64
"T2 plus MTX is an effective and relatively safe treatment for RA patients."( The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.
Li, Y; Shi, Q; Tang, FL; Zhang, FC; Zhang, W; Zhang, X; Zhao, LD, 2010
)
0.64
"All the extracts were found to be safe up to a dose of 2000mg/kg."( Hibiscus vitifolius (Linn.) root extracts shows potent protective action against anti-tubercular drug induced hepatotoxicity.
Ariamuthu, S; Chellappan, DK; Kalusalingam, A; Mohan, S; Samuel, AJ, 2012
)
0.38
" Because chloroform induces toxic effects in the liver and kidneys via production of reactive metabolites, proper characterization of metabolism in these tissues is essential for risk assessment."( Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
Genter, MB; Kedderis, GL; Li, Z; Lipscomb, JC; Rieth, S; Sasso, AF; Schlosser, PM; Snawder, JE, 2013
)
1.04
" The crude extract was less toxic to the Vero cells (LC50=82 µg/ml) than ursolic acid (LC50=25 µg/ml)."( Antifungal activity and cytotoxicity of isolated compounds from leaves of Breonadia salicina.
Eloff, JN; Mahlo, SM; McGaw, LJ, 2013
)
0.39
"The kidney is a primary target for numerous toxic compounds."( The role of renal proximal tubule P450 enzymes in chloroform-induced nephrotoxicity: utility of renal specific P450 reductase knockout mouse models.
Aldous, K; Ding, X; Gu, J; Liu, S; Lu, S; Mei, C; Yao, Y, 2013
)
0.64
" In particular, toxic products might be produced during reaction with disinfectants during the disinfection process."( Chlorination of oxybenzone: Kinetics, transformation, disinfection byproducts formation, and genotoxicity changes.
Wang, X; Xie, YF; Yang, H; Zhang, S, 2016
)
0.43
" The outcomes of interest were safety (measured as adverse events) and efficacy (expressed as recurrence)."( Safety and efficacy of adjunctive therapy in the treatment of odontogenic keratocyst: a systematic review.
Coropciuc, R; Garip, M; Meeus, J; Politis, C; Winters, R, 2023
)
0.91

Pharmacokinetics

The goals of this paper are to develop a biological and pharmacokinetic modeling approach for chloroform. The aim is to evaluate Haber's rule for different ages by taking into account the physiological changes due to growth and aging in rats.

ExcerptReferenceRelevance
"Gastrointestinal (GI) absorption in physiologically based pharmacokinetic models is typically described as first-order transfer from one compartment directly into the liver."( Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description.
Connolly, RB; Fisher, JW; Staats, DA,
)
0.13
" The time course of PBN concentrations in all tissues followed similar curves, and declined rather steeply after the 30-min maximum with a biological half-life of 134 min."( HPLC procedure for the pharmacokinetic study of the spin-trapping agent, alpha-phenyl-N-tert-butyl nitrone (PBN).
Chen, G; Griffin, M; McCay, PB; Poyer, JL, 1990
)
0.28
"A physiologically based pharmacokinetic (PB-PK) model for CHCl3 has been used to prepare estimates of the probability that human populations exposed to low levels of CHCl3 will develop liver tumors similar to those seen in rodent bioassays."( Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling.
Andersen, ME; Conolly, RB; Corley, RA; Gargas, ML; Mendrala, AL; Quast, JF; Reitz, RH; Staats, DA, 1990
)
0.51
"A physiologically based pharmacokinetic model describing the disposition of chloroform in mice, rats, and humans was developed."( Development of a physiologically based pharmacokinetic model for chloroform.
Andersen, ME; Conolly, RB; Corley, RA; Gargas, ML; Mendrala, AL; Reitz, RH; Smith, FA; Staats, DA, 1990
)
0.75
" The present experiments examined these substances for pharmacodynamic differences."( Stereoselectivity of tocainide pharmacodynamics in vivo and in vitro.
Block, AJ; Merrill, D; Smith, ER, 1988
)
0.27
" Comparison pharmacokinetic studies were done with 14CHCl3 and Na(2)14CO3."( Metabolism of [14C]carbon tetrachloride to exhaled, excreted and bound metabolites. Dose-response, time-course and pharmacokinetics.
Farrish, HH; Moslen, MT; Reynolds, ES; Treinen, RJ, 1984
)
0.27
" Very few differences, apart from the change in the nature of the pharmacokinetic model, were seen in the rate coefficients over the dose range tested."( Chlorinated aliphatic hydrocarbons used in the foods industry: the comparative pharmacokinetics of methylene chloride, 1,2 dichloroethane, chloroform and trichloroethylene after I.V. administration in the rat.
Collins, BT; Withey, JR,
)
0.33
" Many pharmacokinetic processes such as metabolism and absorption can be impacted by the presence of other chemicals in the environment and diet and as a result of medication."( Pharmacokinetics, chemical interactions, and toxicological risk assessment in perspective.
Blancato, JN, 1994
)
0.29
" A generalized distributed parameter physiologically-based pharmacokinetic model (DP-PBPK), which describes unsteady state dermal mass flux via a partial differential equation (Fickian diffusion), has been developed for inhalation and dermal absorption of VOCs."( A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds.
Georgopoulos, PG; Lioy, PJ; Roy, A; Weisel, CP, 1996
)
0.29
" In this study, a pharmacokinetic model has been developed to calculate the concentration of CCl4 in the microsomal suspension."( A pharmacokinetic model of anaerobic in vitro carbon tetrachloride metabolism.
Adamovic, JB; Allis, JW; Andersen, ME; Andersen, NJ; Simmons, JE; Thompson, DJ; Waller, CL, 1996
)
0.29
" However, when expressed as the "effective" permeability coefficient (Kpeff), close agreement was noticed between our value and those estimated by others using physiologically based pharmacokinetic (PBPK) models."( Systemic uptake and clearance of chloroform by hairless rats following dermal exposure. I. Brief exposure to aqueous solutions.
Dong, L; Flynn, GL; Islam, MS; McDougal, JN; Zhao, L; Zhou, J, 1996
)
0.58
", 1990: 105, 443) physiologically based pharmacokinetic (PBPK) risk assessment model for chloroform."( Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform.
Allen, BC; Clewell, HJ; Covington, TR, 1996
)
0.72
"A workshop entitled "Implementation of EPA Revised Cancer Assessment Guidelines: Incorporation of Mechanistic and Pharmacokinetic Data" was held in Anaheim, California, in 1996 at the 35th Annual Meeting of the Society of Toxicology (SOT)."( Implementation of EPA Revised Cancer Assessment Guidelines: Incorporation of Mechanistic and Pharmacokinetic Data.
Andersen, ME; Clewell, HJ; Conolly, RB; Farland, W; Frederick, CB; Goodman, JI; Lucier, G; Page, NP; Singh, DV; Yamasaki, H, 1997
)
0.3
" The metabolic elimination amounts at various exposure concentrations were extrapolated using the estimated pharmacokinetic parameters."( Estimation of absorption of trihalomethanes and carbon tetrachloride in low-level exposure by inhalation pharmacokinetic analysis in rats.
Andoh, K; Fukuhara, M; Yoshida, T, 1999
)
0.3
"The kinetics of chloroform in the exhaled breath of human volunteers exposed skin-only via bath water (concentrations < 100 ppb) were analyzed using a physiologically based pharmacokinetic (PBPK) model."( Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures.
Corley, RA; Gordon, SM; Wallace, LA, 2000
)
0.87
" The significant increase in blood concentrations of THMs could be a consequence of pharmacokinetic interactions between two or more of the THMs present simultaneously."( Evaluation of the pharmacokinetic interactions between orally administered trihalomethanes in the rat.
Charest-Tardif, G; Da Silva, ML; Krishnan, K; Tardif, R, 2000
)
0.31
" The goals of this paper are to develop a biological and pharmacokinetic modeling approach for chloroform, and to evaluate Haber's rule for different ages by taking into account the physiological changes due to growth and aging in rats."( A comparison of Haber's rule at different ages using a physiologically based pharmacokinetic (PBPK) model for chloroform in rats.
Boyes, WK; Easterling, MR; Evans, MV; Litton, DK; Simmons, JE, 2002
)
0.75
" To better understand the correlation between biomonitoring data and environmental exposure, physiologically based pharmacokinetic (PBPK) modeling can be of use."( Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform.
Blount, BC; Clewell, HJ; Conolly, RB; Liao, KH; Mason, AM; Tan, YM, 2006
)
0.54
" To use biomonitoring data in understanding exposure, physiologically based pharmacokinetic (PBPK) modeling can be used in a reverse dosimetry approach to assess a distribution of exposures possibly associated with specific blood or urine levels of compounds."( Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling.
Clewell, HJ; Liao, KH; Tan, YM, 2007
)
0.34
" The magnitude of the PK component of the interindividual variability factor (IVF; also referred to as human kinetic adjustment factor (HKAF)) has previously been estimated using Monte Carlo approaches and physiologically based pharmacokinetic (PBPK) models."( Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach.
Krishnan, K; Nong, A, 2007
)
0.34
"Physiologically based pharmacokinetic (PBPK) models are tools for interpreting toxicological data and extrapolating observations across species and route of exposure."( Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
Genter, MB; Kedderis, GL; Li, Z; Lipscomb, JC; Rieth, S; Sasso, AF; Schlosser, PM; Snawder, JE, 2013
)
0.62
" The present study aims to develop a sensitive, rapid and reliable liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the simultaneous estimation of mice plasma concentrations of LTL, WDL and APG using quercetin as an internal standard for the pharmacokinetic analysis."( LC-MS/MS method for the simultaneous quantification of luteolin, wedelolactone and apigenin in mice plasma using hansen solubility parameters for liquid-liquid extraction: Application to pharmacokinetics of Eclipta alba chloroform fraction.
Arya, KR; Arya, RK; Cheruvu, HS; Datta, D; Gayen, JR; Hussain, Z; Sharma, C; Singh, RK; Valicherla, GR; Yadav, NK, 2018
)
0.67

Compound-Compound Interactions

ExcerptReferenceRelevance
"In this work, a dispersive liquid-liquid microextraction (DLLME) procedure combined with ultra-high performance liquid chromatography with diode-array detection was developed to determine 25 antibiotics in mineral and run-off waters."( Dispersive liquid-liquid microextraction combined with ultra-high performance liquid chromatography for the simultaneous determination of 25 sulfonamide and quinolone antibiotics in water samples.
Borges-Miquel, TM; Hernández-Borges, J; Herrera-Herrera, AV; Rodríguez-Delgado, MÁ, 2013
)
0.39
" To simplify sample preparation, in situ derivatization using methyl chloroformate was combined with ultrasound-assisted emulsification microextraction."( A new analytical method to determine non-steroidal anti-inflammatory drugs in surface water using in situ derivatization combined with ultrasound-assisted emulsification microextraction followed by gas chromatography-mass spectrometry.
Jeong, KM; Lee, CH; Lee, J; Nam, MW; Shin, Y, 2014
)
0.64
"A rapid and accurate method for the sensitive detection of illegal drug additives including atenolol (ATN), metformin hydrochloride (MET), and phenformin hydrochloride (PHE) in health products using solvent microextraction (SME) combined with surface-enhanced Raman spectroscopy (SERS) was developed."( Highly sensitive detection of an antidiabetic drug as illegal additives in health products using solvent microextraction combined with surface-enhanced Raman spectroscopy.
He, H; Li, P; Lin, D; Yang, L, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"To improve the limited oral bioavailability of sulpiride, a dosage form containing sodium oleate as an absorption enhancer was developed and evaluated using gastric-emptying-controlled rabbits in a cross-over manner."( Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Iseki, K; Kohri, N; Miyazaki, K; Naasani, I, 1995
)
0.29
" These results strongly suggest that adsorption of quinolones by aluminum hydroxide reprecipitated in the small intestine would play an important role in the reduced bioavailability of quinolones after coadministration with aluminum-containing antacids."( Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.
Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M, 1993
)
0.29
" The risk from copper was highest if bioavailability was not considered, although toxicity correction by a biotic ligand model greatly reduced the estimated risk."( A Bayesian approach to probabilistic ecological risk assessment: risk comparison of nine toxic substances in Tokyo surface waters.
Hayashi, TI; Kashiwagi, N, 2011
)
0.37
"To improve the bioavailability of the decoction, nanoscale SHXXT was developed."( Nanoscale hepatoprotective herbal decoction attenuates hepatic stellate cell activity and chloroform-induced liver damage in mice.
Chang, SJ; Chang, WH; Chen, JJ; Huang, S; Yang, M, 2011
)
0.59
" A small amount of carrier phospholipid significantly increases the rate and the extent of dissolution, which may increase the bioavailability of ibuprofen."( Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance.
Brausch, JF; Hussain, MD; Saxena, V; Talukder, RM, 2012
)
0.38
" The results indicate a way to control the size of cocrystals on a nanometer scale, which will provide higher bioavailability of pharmaceuticals."( Raman Spectroscopy of Pharmaceutical Cocrystals in Nanosized Pores of Mesoporous Silica.
Ajito, K; Ohta, R; Ueno, Y, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The relation of surface polarity and conformational preferences is decisive for cell permeability and thus bioavailability of macrocyclic drugs."( Macrocycle Cell Permeability Measured by Solvation Free Energies in Polar and Apolar Environments.
Hofer, F; Kahler, U; Kamenik, AS; Kraml, J; Liedl, KR; Quoika, PK; Schauperl, M; Waibl, F, 2020
)
0.56
" OTB is poorly absorbed systematically was viable in contrast with different medications used for same purpose, for example, pinaverium bromide and mebeverine, with a good tolerability profile."( A Mini Review on Characteristics and Analytical Methods of Otilonium Bromide.
Mittal, A; Shrivastava, A, 2022
)
0.72

Dosage Studied

Dose-response relationships for trichloroethylene (TCE), allyl alcohol (AA), thioacetamide (TA), and chloroform alone or as mixtures were studied. Hepatic BrdU labeling was increased 40-fold in females (240 mg/kg/day) after 4 days of dosing with chloro Form. Upon daily dosing of chloroForm for 7 days the liver became less susceptible.

ExcerptRelevanceReference
" The dose-response curves in all anesthetics remained unaltered in the presence of either 3 x 10(-7) M dl-propranolol or 1 x 10(-6) M atropine."( Mechanisms of chronotropic effects of volatile inhalation anesthetics.
Krisna, G; Paradise, RR,
)
0.13
" Arguments in favour of the postulated "irreversibility" of carcinogenic effects are based on dose-response studies, single-dose and multi-generation experiments as well as on the concept of somatic mutation as the first steps in carcinogenesis with subsequent transmittance of induced defects during cell replication."( Toxicological aspects of food safety - carcinogenicity and mutagenicity.
Preussmann, R, 1978
)
0.26
"Rats were dosed once, 5 times or 10 times with chloroform (0."( Effect of chloroform on the activities of liver enzymes in rats.
Grey, TF; Groger, WK, 1979
)
0.92
" These permit the elaboration of dose-response lines for the substances in question, the calculation of median effective doses and the statistical analysis of differences in liver-damaging potency."( Quantitative aspects in the assessment of liver injury.
Plaa, GL, 1976
)
0.26
" Males pretreated with MCA had 45-fold greater plasma alanine aminotransferase (ALT) compared to the saline pretreated group similarly dosed with CHCl3."( Sex differences in monochloroacetate pretreatment effects on chloroform toxicity in rats.
Berndt, WO; Davis, ME, 1992
)
0.52
" Optimization of the KAS, KAD, and KT values for each dosing solution allowed accurate simulation of each data set."( Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description.
Connolly, RB; Fisher, JW; Staats, DA,
)
0.13
"98 per cent in regard to the substance and its dosage form (gynecological suppositories), respectively."( [A method of quantitative analysis of gentamicin sulfate].
Likhoded, VA; Mukhamedzianov, RM, 1991
)
0.28
" Moreover, the minimally effective dosage needed to potentiate CHCl3-induced hepatotoxicity was approximately 5 mmol/kg for the three compounds."( Potentiation of chloroform-induced hepatotoxicity by methyl isobutyl ketone and two metabolites.
du Souich, P; Greselin, E; Kobusch, AB; Plaa, GL; Vézina, M, 1990
)
0.63
" Following the pretreatment at various time intervals ranging from 10 to 96 hr, groups of animals received a challenging dosage of CHCl3 (0."( Modifications in rat hepatobiliary function following treatment with acetone, 2-butanone, 2-hexanone, mirex, or chlordecone and subsequently exposed to chloroform.
Ayotte, P; Hewitt, LA; Plaa, GL, 1986
)
0.47
"Using the rat liver foci bioassay a dose-response relationship was evaluated for the promoting activity of the ubiquitous and persistent environmental pollutants polychlorinated biphenyls (PCBs) and chloroform."( Dose-response of promotion by polychlorinated biphenyls and chloroform in rat liver foci bioassay.
Deml, E; Oesterle, D, 1987
)
0.7
" When the dosing interval between the first and second dose was varied from 1 to 31 days, the magnitude of the resistance to further stimulation by chloroform only decreased gradually."( Chloroform mediated refractory state against ornithine decarboxylase induction by serial chloroform treatment.
DeAngelo, AB; Guion, C; Pereira, MA; Savage, RE, 1988
)
1.92
" Addition of naloxone to propranolol shifted the dose-response curve of propranolol to the left significantly, indicating an additive effect of the two drugs in their antiarrhythmic activity."( Cardiac antiarrhythmic evaluation of naloxone with or without propranolol using a modified chloroform-hypoxia screening test in the rat.
Lee, AY; Wong, TM,
)
0.35
"These studies were designed to provide dose-response relationships for chlordecone (CD) potentiation of BrCCl3 hepatotoxicity in male rats using biochemical, functional and histopathological parameters."( Potentiation of bromotrichloromethane hepatotoxicity and lethality by chlordecone preexposure in the rat.
Agarwal, AK; Mehendale, HM,
)
0.13
" The CHCl3 challenge dosage (0."( Dose-response relationships in ketone-induced potentiation of chloroform hepato- and nephrotoxicity.
Brown, EM; Hewitt, WR, 1984
)
0.51
"The association between gastrointestinal, urinary tract, brain, lung, and breast cancer mortality and drinking water trihalomethane exposure, as estimated by average daily chlorine dosage of water source 20 years past, was investigated for Wisconsin white females by use of a death certificate-based case-control study design."( Epidemiologic study of drinking water chlorination and Wisconsin female cancer mortality.
Kanarek, MS; Tsiatis, AA; Young, TB, 1981
)
0.26
" The degree and onset of these pathological changes were directly and inversely proportional, respectively, to the dosage of killed organisms administered."( Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice.
Cantrell, JL; Williams, JC, 1982
)
0.26
" Upon daily dosing of chloroform for 7 days the liver became less susceptible, with the last dose of chloroform resulting in only 10% of the activity observed after a single dose."( Chloroform induction of ornithine decarboxylase activity in rats.
Guion, C; Pereira, MA; Savage, RE; Westrich, C, 1982
)
2.02
" The dose-response and time-action parameters of theophylline's predisposing action to chloroform-hypoxia-induced cardiac arrhythmias were determined."( Development of a cardiac antiarrhythmic screening test utilizing theophylline in the rat.
Baker, T; Erker, EF, 1980
)
0.48
" Data points were collected nine times during the dosing period and twice after dosing had ceased."( Distribution of volatile halogenated organic compounds between rat blood serum and adipose tissue.
Enos, HF; Peoples, AJ; Pfaffenberger, CD, 1980
)
0.26
" For example, while DNA reactive-carcinogens would still be assumed to have linear low-dose risk, carcinogens acting through purely cytotoxic mechanisms might be assumed to have sharply non-linear or even threshold dose-response curves."( Cancer and non-cancer risk assessment: not so different if you consider mechanisms.
Conolly, RB, 1995
)
0.29
"The traditional multistage (MS) model of carcinogenesis implies several empirically testable properties for dose-response functions."( An exact analysis of the multistage model explaining dose-response concavity.
Cox, LA, 1995
)
0.29
" Sensible public health decisions are made more certain through the use of mechanistic information throughout the 4 steps in RA: hazard identification, dose-response assessment, exposure (dose) assessment and risk characterisation."( Use of mechanistic information in risk assessment for toxic chemicals.
Becking, GC, 1995
)
0.29
" Dose-response relationships for A, MEK, and MiBK potentiation of CCl4-induced hepatotoxicity and CHCl3-induced nephrotoxicity were compared."( Ketone potentiation of haloalkane-induced hepato- and nephrotoxicity. I. Dose-response relationships.
Plaa, GL; Raymond, P, 1995
)
0.29
"To improve the limited oral bioavailability of sulpiride, a dosage form containing sodium oleate as an absorption enhancer was developed and evaluated using gastric-emptying-controlled rabbits in a cross-over manner."( Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Iseki, K; Kohri, N; Miyazaki, K; Naasani, I, 1995
)
0.29
" These observations define the dose-response relationships for the liver, kidneys and nasal passages as target organs for chloroform administered by gavage in the female F-344 rat."( Toxicity and cell proliferation in the liver, kidneys and nasal passages of female F-344 rats, induced by chloroform administered by gavage.
Butterworth, BE; Larson, JL; Méry, S; Morgan, KT; Wolf, DC, 1995
)
0.71
" Experts in cancer biology/toxicology, pharmacokinetics, and dose-response modeling were identified by a panel of science-policy specialists."( Use of probabilistic expert judgment in uncertainty analysis of carcinogenic potency.
Evans, JS; Graham, JD; Gray, GM; Sielken, RL; Smith, AE; Valdez-Flores, C, 1994
)
0.29
"The task of fitting dose-response models to experimental data can be performed using a spreadsheet with a built-in optimization engine."( Dose-response analysis using spreadsheets.
Haas, CN, 1994
)
0.29
" 3 and 10 days and 1, 3 and 6 months) and a dose-response experiment."( A unique pattern of hepatocyte proliferation in F344 rats following long-term exposures to low levels of a chemical mixture of groundwater contaminants.
Baker, DC; Benjamin, SA; Constan, AA; Yang, RS, 1995
)
0.29
" Thus, the most straightforward risk assessment for chloroform for this tissue would assign no increased cancer risk for dosing regimens that do not induce cytolethality and cell proliferation."( Induced cytotoxicity and cell proliferation in the hepatocarcinogenicity of chloroform in female B6C3F1 mice: comparison of administration by gavage in corn oil vs ad libitum in drinking water.
Butterworth, BE; Larson, JL; Wolf, DC, 1994
)
0.77
"5 mM) by 20% of the control in the in situ ligated loop experiment, in which partial precipitation of aluminum hydroxide was observed in the dosing solution."( Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.
Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M, 1993
)
0.29
" Chloroform-induced cell killing was inferred quantitatively from dose-response hepatic labelling index studies conducted in female B6C3F1 mice and male F344 rats."( Biologically based dose response model for hepatic toxicity: a mechanistically based replacement for traditional estimates of noncancer risk.
Butterworth, BE; Conolly, RB, 1995
)
1.2
" Rats dosed orally (100 mg/kg) were fully protected from VF."( Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Brooks, RR; Carpenter, JF; Maynard, AE; Miller, KE, 1996
)
0.29
" Dose-response curves, based on total amount of CCl4 added to the microsomes, revealed a nonlinear, biphasic appearance of CHCl3, with fasting slightly increasing CHCl3 production in microsomes prepared from fasted rats."( A pharmacokinetic model of anaerobic in vitro carbon tetrachloride metabolism.
Adamovic, JB; Allis, JW; Andersen, ME; Andersen, NJ; Simmons, JE; Thompson, DJ; Waller, CL, 1996
)
0.29
" The present study was designed to investigate the dose-response relationships for chloroform-induced lesions and regenerative cell proliferation in B6C3F1 mice as the basis for formulation of a biologically based risk assessment for inhaled chloroform."( A 90-day chloroform inhalation study in female and male B6C3F1 mice: implications for cancer risk assessment.
Butterworth, BE; Conolly, RB; Jamison, KC; Larson, JL; Leininger, JR; Méry, S; Morgan, KT; Templin, MV; Wolf, DC; Wong, BA, 1996
)
0.94
"A method is described for the assessment of the dissolution behavior of solid dosage forms with a high content of a very water insoluble drug."( Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets.
Hoa, NT; Kinget, R, 1996
)
0.29
" The preparations satisfying sustained release dosage form of Ibuprofen was also investigated."( Drug release from lipid matrices. Part II. Influence of formulation factors on the release of slightly soluble drug.
Ozates, B; Ozdemir, N,
)
0.13
" Each of these four THMs was carcinogenic in rodents in chronic oral dosing studies."( Glutathione S-transferase-mediated mutagenicity of trihalomethanes in Salmonella typhimurium: contrasting results with bromodichloromethane off chloroform.
Andersen, ME; Claxton, LD; Pegram, RA; Ross, TM; Warren, SH, 1997
)
0.5
" The purpose of our study was to assess the influence of oral dosing vehicle on the acute hepatotoxicity of CCl4 and nephrotoxicity of CHCl3."( Effect of dosing vehicle on the hepatotoxicity of CCl4 and nephrotoxicity of CHCl3 in rats.
Plaa, GL; Raymond, P, 1997
)
0.3
" Histopathology revealed degenerative changes in olfactory mucosa and underlying ethmoid turbinate bones that were essentially identical in nature and severity, including dose-response and progression, to those reported previously for chloroform gavage (Larson et al."( Chloroform-induced olfactory mucosal degeneration and osseous ethmoid hyperplasia are not associated with olfactory deficits in Fischer 344 rats.
D'Antonio, A; Dorman, DC; James, RA; Miller, KL; Morgan, KT, 1997
)
1.92
" Recent data on chloroform indicate that the dose-response relationship for chloroform-induced tumors in rats and mice is nonlinear, based upon events secondary to cell necrosis and subsequent regeneration as the likely mode of action for the carcinogenic effects of chloroform."( Chloroform mode of action: implications for cancer risk assessment.
Golden, RJ; Holm, SE; Julkunen, PH; Reese, EA; Robinson, DE, 1997
)
2.09
" To date, no comprehensive comparison of the acute renal and hepatic effects of BDCM and CHCl3 following oral gavage in an aqueous dosing vehicle has been conducted."( Trihalomethane comparative toxicity: acute renal and hepatic toxicity of chloroform and bromodichloromethane following aqueous gavage.
Lilly, PD; Pegram, RA; Ross, TM, 1997
)
0.53
" This study compares dose-response relationships of gavage-administered chlorinated/brominated trihalomethanes for hepatotoxicity, replicative DNA synthesis, and hepatocarcinogenicity in female B6C3F1 mice."( Regenerative hyperplasia is not required for liver tumor induction in female B6C3F1 mice exposed to trihalomethanes.
Dunnick, JK; Kohn, MC; Leininger, JR; Melnick, RL, 1998
)
0.3
" Because chloroform is not a DNA reactive mutagen, a 13-week time-course and dose-response study was conducted under conditions of the original bioassay to examine whether regenerative cell proliferation was an underlying mechanism of carcinogenesis."( Patterns of chloroform-induced regenerative cell proliferation in BDF1 mice correlate with organ specificity and dose-response of tumor formation.
Butterworth, BE; Constan, AA; Templin, MV; Wolf, DC; Wong, BA, 1998
)
1.1
" Dose-response relationships for trichloroethylene (TCE), allyl alcohol (AA), thioacetamide (TA), and chloroform alone or as mixtures were studied."( Toxicant-inflicted injury and stimulated tissue repair are opposing toxicodynamic forces in predictive toxicology.
Clewell, H; Mehendale, HM; Mumtaz, MM; Ramaiah, SK; Soni, MG, 1999
)
0.52
" The proposal marked a departure from the agency's traditional reliance on linear dose-response models in performing risk assessment, and reflected the new thinking contained in the 1996 draft update to the agency's cancer risk assessment guidelines."( Chloroform: An EPA test case.
Schmidt, CW, 1999
)
1.75
" Hepatic BrdU labeling was increased 40-fold in females (240 mg/kg/day) and 20-fold in males (140 mg/kg/day) after 4 days of dosing with chloroform."( V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury.
Delker, DA; Gollapudi, BB; Yano, BL, 1999
)
0.51
"0 ml/kg DMSO at 24 hr after toxicant dosing and then killing the animals at 48 hr."( Hepatoprotection by dimethyl sulfoxide. II. Characterization of optimal dose and the latest time of administration for effective protection against chloroform and bromobenzene induced injury.
Gandolfi, AJ; Lind, RC, 1999
)
0.5
" These new guidelines provide the latitude to consider diverse scientific data and allow considerable flexibility in dose-response assessments, depending on the chemical's mode of action."( Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds.
Andersen, ME; Boorman, GA; Brusick, DJ; Cohen, SM; Dragan, YP; Frederick, CB; Goodman, JI; Hard, GC; Meek, ME; O'Flaherty, EJ; Robinson, DE, 2000
)
0.31
" However, the toxicity and carcinogenicity of these substances is profoundly affected by dosing in corn oil."( Risk assessment case study--chloroform and related substances.
Fawell, J, 2000
)
0.6
" Plasma ALT activities and quantitation of liver injury by light microscopy at 48 h after CHCl(3) dosing indicated that all three treatments were equally effective at protecting the liver."( Hepatoprotection by dimethyl sulfoxide. III. Role of inhibition of the bioactivation and covalent bonding of chloroform.
Begay, CK; Gandolfi, AJ; Lind, RC, 2000
)
0.52
" The practical upper limits of dosage were found to be 1, 500 mg-Al/L and 1,000 mg-Fe/L, respectively, for Al- and Fe-based coagulants."( Recovery of poly(3-hydroxybutyrate) from coagulated Ralstonia eutropha using a chemical digestion method.
Chang, YK; Cho, KS; Lee, EG; Ryu, HW,
)
0.13
"The dose and time dependence of formation of a specific adduct between mitochondrial phospholipid and phosgene have been determined in the liver of Sprague-Dawley (SD) rats as well as in the liver and kidney of B6C3F1 mice after dosing with chloroform."( Correlation of a specific mitochondrial phospholipid-phosgene adduct with chloroform acute toxicity.
De Angelis, G; Di Consiglio, E; Testai, E; Vittozzi, L, 2001
)
0.72
" Biomasses with different activities were used as inocula, and inhibition was induced by dosing chloroform according to two different procedures."( Inhibiting effects of chloroform on anaerobic microbial consortia as monitored by the Rantox biosensor.
Di Pinto, AC; Laera, G; Pollice, A; Rozzi, A; Tomei, MC, 2001
)
0.84
" Three-dimensional dose-response surfaces for liver toxicity were generated for each age group of interest: adolescent, adult, and senescent rats."( A comparison of Haber's rule at different ages using a physiologically based pharmacokinetic (PBPK) model for chloroform in rats.
Boyes, WK; Easterling, MR; Evans, MV; Litton, DK; Simmons, JE, 2002
)
0.53
" In this study, NS-398, a specific COX-2 inhibitor, and indomethacin, a COX-1 and COX-2 inhibitor, were administered 24 h after chloroform dosing to determine their effect on liver injury in Sprague-Dawley rats."( Late administration of COX-2 inhibitors minimize hepatic necrosis in chloroform induced liver injury.
Begay, CK; Gandolfi, AJ, 2003
)
0.76
" The proposed method was applied successfully to the determination of NMS in pure and dosage forms, with a good precision and accuracy compared to the official one."( Ion-association method for the colorimetric determination of neomycin sulphate in pure and dosage forms.
Amin, AS; Issa, YM, 2003
)
0.32
" H2O2 was dosed at later reaction time points to initiate Fenton or photo-Fenton reactions."( Fe0-based system as innovative technology for degrading trichloromethane: redox removal characteristics.
Huang, CI; Liao, CH; Lu, MC; Wantawin, C, 2004
)
0.32
" Dose-response relationships, a criterion for causality, were examined linking exposures to likelihood of case status."( Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures.
Baines, CJ; Cole, DE; Jazmaji, V; Loescher, B; Marshall, L; McKeown-Eyssen, GE; Riley, N, 2004
)
0.32
" On the other hand, tissue repair showed a dose-response leading to regression of injury."( Dose-dependent liver regeneration in chloroform, trichloroethylene and allyl alcohol ternary mixture hepatotoxicity in rats.
Anand, SS; Mehendale, HM; Mumtaz, MM, 2005
)
0.6
" The proposed methods were checked using laboratory-prepared mixtures and were successfully applied for the analysis of pharmaceutical formulations containing the above drugs with no interference from other dosage form additives."( Determination of nifuroxazide and drotaverine hydrochloride in pharmaceutical preparations by three independent analytical methods.
Abdelkawy, M; Metwally, FH; Naguib, IA,
)
0.13
" The levels of chloroform were measured in blood, liver, and kidney during the dosing regimen (1, 7, 14, and 30 days)."( Adaptive tolerance in mice upon subchronic exposure to chloroform: Increased exhalation and target tissue regeneration.
Anand, SS; Latendresse, JR; Mehendale, HM; Mumtaz, MM; Palkar, PS; Philip, BK, 2006
)
0.93
" In subsequent dosing studies, PCE oxidation served as an indicator of Fenton reactions, while OA assimilation, dissolved oxygen (DO) concentration, and heterotrophic plate counts were indicators of aerobic microbial activity."( Effect of Fenton reagent dose on coexisting chemical and microbial oxidation in soil.
Bou-Nasr, J; Cassidy, D; Ndjou'ou, AC, 2006
)
0.33
" The proposed developed HPTLC method can be applied for identification and quantitative determination of imatinib mesylate in bulk drug and dosage forms."( Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form.
Musmade, P; Subramanian, G; Vadera, N, 2007
)
0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" Male C57BL/6 mice on a high-fat diet for 2 months when challenged with dexamethasone showed elevated food consumption and weight gain relative to age and diet-matched animals dosed with saline only."( Effect of dexamethasone on glucose tolerance and fat metabolism in a diet-induced obesity mouse model.
Argentieri, G; Gounarides, JS; Killary, K; Korach-André, M; Laurent, D; Turner, O, 2008
)
0.35
"The independent activity test and the hypnotic synergism test by sub-threshold hypnotic dosage of pentobarbital were employed to evaluate the central pharmacological effect of the extract-compounds, and the minimal neurotoxicity was evaluated by the rotorod test."( [Hypnotic effect of Chinese materia medica Cynanchum chinese in mice].
Peng, JZ; Peng, XD; Wang, R; Yan, QS; Yang, WD, 2007
)
0.34
" In this study, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model that links the processes of chloroform metabolism, reparable cell damage, cell death, and regenerative cellular proliferation was developed to support a new cancer dose-response assessment for chloroform."( Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
Andersen, ME; Borghoff, SJ; Clewell, HJ; Conolly, RB; Gargas, ML; Liao, KH; Tan, YM, 2007
)
0.76
" Results of these studies confirmed low dosage bicarbonate affecting the ozonation pathways, influencing the intermediate species formation and impacting its subsequent TCMFP yields through inhibiting the ."( Effect of preozonation on the characteristic transformation of fulvic acid and its subsequent trichloromethane formation potential: presence or absence of bicarbonate.
Li, J; Liu, H; Liu, R; Qu, J; Ru, J; Zhao, X, 2008
)
0.35
" Extrapolation from empirical dose-response relationships obtained in experimental studies has been criticized, as it fails to take into account information on mode of action."( Mode of action considerations in the quantitative assessment of tumour responses in the liver.
Boobis, AR, 2010
)
0.36
"Biologically based dose-response (BBDR) modeling of environmental pollutants can be utilized to inform the mode of action (MOA) by which compounds elicit adverse health effects."( Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
Conolly, RB; DeVito, MJ; El-Masri, HA; Luke, NS; Sams, R, 2010
)
0.36
" One such tool is the International Life Sciences Institute (ILSI) Key Events Dose-Response Framework (KEDRF)."( Application of the International Life Sciences Institute Key Events Dose-Response Framework to food contaminants.
Fenner-Crisp, PA, 2012
)
0.38
" Benchmark dose (BMD) modeling is used to characterize the dose-response relationship of kidney toxicity markers as a function of PBPK-derived internal kidney dose."( Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
Genter, MB; Kedderis, GL; Li, Z; Lipscomb, JC; Rieth, S; Sasso, AF; Schlosser, PM; Snawder, JE, 2013
)
0.62
" The proposed method was successfully applied to the analysis of the cited drugs in dosage forms."( Highly sensitive spectrofluorimetric method for determination of certain aminoglycosides in pharmaceutical formulations and human plasma.
Aly, AA; Hammad, MA; Nagy, DM; Omar, MA, 2013
)
0.39
"Six-week old rats were orally administered with the extract at dosage levels of 100 mg/kg, 300 mg/kg and 1000 mg/kg for 28 days."( Sub-acute toxicity of the chloroformic extract of Rapanea melanophloeos (L.) Mez in rats.
Amenya, HZ; Gathumbi, PK; Mbaria, JM; Thaiyah, AG; Thoithi, GN, 2014
)
0.7
"Our results demonstrate that the chloroformic stem bark extract of Rapanea melanophloeos may be of no toxicological concern at dosage levels up to 1000mg/kg."( Sub-acute toxicity of the chloroformic extract of Rapanea melanophloeos (L.) Mez in rats.
Amenya, HZ; Gathumbi, PK; Mbaria, JM; Thaiyah, AG; Thoithi, GN, 2014
)
0.98
" Dosing the films on the interdigitated electrodes with methanol, ethanol, chloroform and toluene vapors increased the film resistance of CNT-CS but decreased the resistance of CNT-CS-PCL compared to that of the reported transducers."( Chitosan and chitosan-co-poly(epsilon-caprolactone) grafted multiwalled carbon nanotube transducers for vapor sensing.
Akhtar, S; Chatterjee, S; Ha, CS; Mishra, S; Rana, VK; Singh, RP, 2014
)
0.63
" fomentarius CHCl3 fraction could inhibit proliferation of K562 cells depending on both the dosage and the incubation time, cause cell membrane damage, influence intracellular [Ca(2+)]i variation, promote the yield of ROS, decrease the level of Δψ m, and initiate the apoptotic response in K562 cells."( Chemical compositions and antiproliferation activities of the chloroform fraction from Pyropolyporus fomentarius in K562 cells.
Liu, Q; Wang, P; Wang, X; Xiao, Y; Yang, S; Zhang, Y, 2015
)
0.66
" All kinds of DBPs detected increased with the dosage of increasing chlorine, but the increases slowed down when the dosage was higher than 2 mg ."( [Formation of Disinfection By-Products During Chlor(am)ination of Danjiangkou Reservoir Water and Comparison of Disinfection Processes].
Cheng, T; Chu, WH; Xia, SJ; Xu, B; Zhang, MS; Zhang, TY, 2015
)
0.42
" Here, metabolic profiles for aniline (A), chloroform (CL), ethylbenzene (EB), 2-methoxyethanol (ME), N,N-dimethylformamide (DMF) and tetrahydrofurane (THF), dosed inhalatively for six hours/day, five days a week for 4 weeks were compared to oral dosing performed daily for 4 weeks."( Metabolite profiles of rats in repeated dose toxicological studies after oral and inhalative exposure.
Bordag, N; Fabian, E; Herold, M; Kamp, H; Krennrich, G; Looser, R; Ma-Hock, L; Mellert, W; Montoya, G; Peter, E; Prokudin, A; Spitzer, M; Strauss, V; van Ravenzwaay, B; Walk, T; Zbranek, R, 2016
)
0.7
" Haematological parameters are an important indicator of human well-being which is why the prime objective of the current study was to conduct a dose-response assessment to investigate the effects of trihalomethanes on human haematological count."( Effect of trihalomethanes (chloroform and bromoform) on human haematological count.
Hashmi, I; Khan, R; Lodhi, A; Nasir, H, 2017
)
0.75
" However, a dose-response function (DRF), informed by various levels of information including apical health response, can represent a template for convergent top-down, bottom-up analysis."( A general dose-response relationship for chronic chemical and other health stressors and mixtures based on an emergent illness severity model.
Chiu, WA; Englehardt, JD, 2019
)
0.51
" Formula granules have become the preferred method for delivery of herbal formulation in China given its benefit of potency retention, dosing precision and ease of use."( Aqueous extraction from dachengqi formula granules reduces the severity of mouse acute pancreatitis via inhibition of pancreatic pro-inflammatory signalling pathways.
Chvanov, M; Criddle, DN; Deng, L; Du, D; Fu, X; Han, C; Huang, W; Jiang, K; Jin, T; Lan, T; Liang, G; Liu, T; Ma, X; Nunes, QM; Philips, AR; Shi, N; Sutton, R; Wen, Y; Windsor, JA; Xia, Q; Yang, J, 2020
)
0.56
" The effects are long lasting, even after stopping the dosage regime for reduction of abdominal pain."( A Mini Review on Characteristics and Analytical Methods of Otilonium Bromide.
Mittal, A; Shrivastava, A, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
inhalation anaestheticnull
non-polar solventnull
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
central nervous system drugA class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system.
refrigerantA substance used in a thermodynamic heat pump cycle or refrigeration cycle that undergoes a phase change from a gas to a liquid and back. Refrigerants are used in air-conditioning systems and freezers or refrigerators and are assigned a "R" number (by ASHRAE - formerly the American Society of Heating, Refrigerating and Air Conditioning Engineers), which is determined systematically according to their molecular structure.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
chloromethanesA halomethane that is methane in which one or more hydrogens has been replaced by chlorine.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency40.53340.007215.758889.3584AID624030
interleukin 8Homo sapiens (human)Potency84.12670.047349.480674.9780AID651758
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.53123.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency49.58990.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency27.08400.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency68.03200.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency68.03200.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency38.87650.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency56.14680.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency74.19810.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency64.71160.000229.305416,493.5996AID1259244; AID1259248; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency1.77830.001024.504861.6448AID588535
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency3.86050.023723.228263.5986AID743222
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency54.53120.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency125.86600.039147.5451146.8240AID1224845
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency28.18380.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.03200.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency34.09680.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.03200.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency74.97800.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (134)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID112346Evaluated in vitro for anesthetic activity in mice and ED50 value was reported1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1090713Thrips luring activity against female New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID603952In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID107968Evaluated in vitro for anesthetic activity in man and minimum alveolar concentration (MAC) was determined1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID1090711Thrips luring activity against female Thrips tabaci (onion thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID168703Inhibition of Rana pipiens muscle activity.1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID212400Toxicity determined using Tadpole Narcosis Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID540235Phospholipidosis-negative literature compound
AID1090712Thrips luring activity against male New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID603951In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID19825Partition coefficient (logP)1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID59016Evaluated in vitro for anesthetic activity in dog and minimum alveolar concentration (MAC) was determined1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1145366Octanol-water partition coefficient, log P of the compound1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Application of SCAP to drug design. 1. Prediction of octanol-water partition coefficients using solvent-dependent conformational analyses.
AID37562Induction of aneuploidy in Aspergillus nidulans.1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID28398Partition coefficient was determined in oil/gas system and value was reported1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID162229Toxicity determined using Konemann's Industrial Pollutants Toxicity Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID603950In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346652Human K2P16.1 (Two P domain potassium channels)2001Biochemical and biophysical research communications, Mar-23, Volume: 282, Issue:1
Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
AID1346604Human K2P2.1 (Two P domain potassium channels)1999Nature neuroscience, May, Volume: 2, Issue:5
Inhalational anesthetics activate two-pore-domain background K+ channels.
AID1346672Human K2P17.1 (Two P domain potassium channels)2001Biochemical and biophysical research communications, Mar-23, Volume: 282, Issue:1
Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,217)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902997 (48.21)18.7374
1990's708 (11.39)18.2507
2000's1076 (17.31)29.6817
2010's1117 (17.97)24.3611
2020's319 (5.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.05 (24.57)
Research Supply Index8.82 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index196.17 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (102.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (0.60%)5.53%
Reviews149 (2.22%)6.00%
Case Studies121 (1.80%)4.05%
Observational1 (0.01%)0.25%
Other6,394 (95.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]